Skip to search formSkip to main contentSkip to account menu

RADIUM CHLORIDE RA-223

Known as: RADIUM RA-223 DICHLORIDE 
National Institutes of Health

Related topics

Related topics

4 relations
6 ML RADIUM CHLORIDE RA-223 30 MCI/ML Injection [Xofigo]Alpharadinradium Ra 223 dichloride

Narrower (1)

Xofigo

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation
Radium-223 dichloride (Ra-223) is the first targeted alpha therapy approved for the treatment of patients with castration… 
2017
2017
Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
158Background: Ra-223, a targeted alpha therapy, is currently used to treat mCRPC patients (pts). To investigate Ra-223 when used… 
2015
2015
Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting.
253 Background: The aim of this prospective early-access program (EAP) was to monitor acute and long-term safety of Ra-223 CL2… 
2014
2014
Alphastrahler Radium-223-Dichlorid
ZusammenfassungRadium- (Ra-)223-Dichlorid ist ein Alphastrahler zur Behandlung des kastrationsresistenten Prostatakarzinoms (CRPC… 
Review
2012
Review
2012
Safety of Cytotoxic Chemotherapy Following Radium-223 Chloride (RA-223) Therapy in the Phase 3 Alsympca Study in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)